Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Cerity Partners LLC

Cerity Partners LLC lowered its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 6.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,968 shares of the company’s stock after selling 4,556 shares during the period. Cerity Partners LLC’s holdings in Takeda Pharmaceutical were worth $899,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Hexagon Capital Partners LLC grew its position in Takeda Pharmaceutical by 65.7% in the third quarter. Hexagon Capital Partners LLC now owns 5,548 shares of the company’s stock worth $86,000 after buying an additional 2,199 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Takeda Pharmaceutical by 91.1% in the 4th quarter. Blue Trust Inc. now owns 5,837 shares of the company’s stock worth $91,000 after acquiring an additional 2,782 shares during the last quarter. Allworth Financial LP raised its position in shares of Takeda Pharmaceutical by 111.2% during the third quarter. Allworth Financial LP now owns 6,183 shares of the company’s stock worth $96,000 after purchasing an additional 3,256 shares during the period. New York State Common Retirement Fund purchased a new stake in shares of Takeda Pharmaceutical during the third quarter valued at $145,000. Finally, Bruce G. Allen Investments LLC acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at $138,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Trading Up 0.9 %

Shares of TAK opened at $13.36 on Tuesday. Takeda Pharmaceutical Company Limited has a 1-year low of $13.11 and a 1-year high of $17.11. The business’s 50-day moving average price is $14.16 and its 200 day moving average price is $14.24. The stock has a market capitalization of $42.28 billion, a P/E ratio of 20.24, a P/E/G ratio of 3.74 and a beta of 0.53. The company has a current ratio of 1.06, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.51 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. The business had revenue of $7.52 billion for the quarter. Analysts expect that Takeda Pharmaceutical Company Limited will post 1.5 earnings per share for the current year.

Insider Activity

In related news, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the company’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $8.10, for a total transaction of $29,999,994.30. Following the transaction, the insider now directly owns 3,755,583 shares of the company’s stock, valued at $30,420,222.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.04% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.